Keeping blood pressure under control is critical. There’s a new option for tough cases
About half of U.S. adults have high blood pressure and too few have it under control. Now some patients who've tried ...
Piper Sandler cuts Keros stock target to $15, keeps Overweight
Piper Sandler adjusted its outlook on Keros Therapeutics (NASDAQ:KROS), significantly reducing the price target from $40.00 ...
pulmonologyadvisor3d
Exercise Pulmonary Hypertension Independently Predicts Survival in Some Patients
Exercise PH — measured by the mPAP/CO slope — may predict survival in patients with normal or mildly elevated pulmonary arterial pressure.
Pulmonaryhypertensionnews.com3d
Winrevair regimen balances efficacy, safety in PAH: Analysis
The dosing regimen for Winrevair is optimal for balancing safety and effectiveness in adults with PAH, according to clinical ...
Daily4d
Servier Introduces Cosyrel: A Novel SPC for Hypertension and Post-MI Care
Servier India Pvt. Ltd. has launched a single-pill combination (SPC) of Bisoprolol/Perindopril in India under the brand name ...
health.economictimes.indiatimes4d
Keros halts blood pressure treatment trial on safety issues
The company was testing its therapy, cibotercept, in patients with pulmonary arterial hypertension (PAH) - a rare disease ...
The Lancet4d
Global and European landscape of major hypertension guidelines
Elevated blood pressure is the most important risk factor for cardiovascular disease. Numerous clinical practice guidelines ...
Things You Probably Don't Know About Viagra (Like What It Was Originally Used For)
Whether you’re a senior in high school or a senior-living resident, you’ve likely heard of Viagra (sildenafil) — the original ...
The Pharma Letter5d
Keros Therapeutics drops another Phase II cibotercept trial
US clinical-stage pharma Keros Therapeutics today announced that it has voluntarily halted all dosing in the TROPOS trial, a ...
Keros Therapeutics Shares Down After Halting Pulmonary Hypertension Treatment Trials
Shares in Keros Therapeutics fell sharply Wednesday morning after it said it halted trials of its treatment for pulmonary hypertension after finding adverse health effects in patients trialing the ...
FierceBiotech5d
Keros, after halting 2 cohorts over fluid buildups around heart, pulls plug on hypertension trial
A month after halting dosing in two of the three treatment arms of a phase 2 trial of its pulmonary arterial hypertension ...
Keros Therapeutics Halts Pulmonary Hypertension Treatment Trials Due to Adverse Effects
Keros Therapeutics has halted the dosing of its treatment for pulmonary hypertension due to adverse health effects discovered during trials. The clinical-stage biopharmaceutical company said Wednesday ...